Limits...
Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy.

Hong J, Woo HS, Kim H, Ahn HK, Sym SJ, Park J, Ahn JY, Cho EK, Shin DB, Lee JH - Cancer Sci. (2014)

Bottom Line: This finding was observed irrespective of the status of pre-treatment bone marrow involvement.In multivariate analysis, hemoglobin <10 g/dL was found to be an international prognostic index-independent prognostic factor.Risk of relapse was significantly higher for patients who were still anemic at 6 months after R-CHOP, compared to those who achieved complete recovery from chemotherapy-induced anemia within 6 months.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University School of Medicine, Incheon, Korea.

Show MeSH

Related in: MedlinePlus

Analyses of the impact of anemia on treatment outcomes in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy (n = 157). (a, b) Kaplan–Meier plots for event-free survival according to the grade of baseline anemia. (c) Kaplan–Meier plot for disease-free survival according to the grade of baseline anemia. (d, e) Kaplan–Meier graphs for event-free survival according to bone marrow status and baseline anemia.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317957&req=5

fig01: Analyses of the impact of anemia on treatment outcomes in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy (n = 157). (a, b) Kaplan–Meier plots for event-free survival according to the grade of baseline anemia. (c) Kaplan–Meier plot for disease-free survival according to the grade of baseline anemia. (d, e) Kaplan–Meier graphs for event-free survival according to bone marrow status and baseline anemia.

Mentions: The mean baseline Hb was 11.9 ± SD 1.8 g/dL in male patients and 10.9 ± SD 1.6 g/dL in female patients (P = 0.001). One hundred and twenty-one patients (77.1%) had G ≥ 1 and 34 patients (21.7%) had G ≥ 2 baseline anemia. Patients with a CIA of G ≥ 2 anemia showed inferior EFS compared to those with no (G0) or G1 anemia (Fig. 1a,b). Among 10 patients who had TRM, 7 had G ≥ 2 baseline anemia (P = 0.001). However, such a significant difference of survival between patients with G ≥ 2 anemia and those with G0 or 1 anemia was well maintained in analysis of DFS instead of EFS (P < 0.001; Fig. 1c).


Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy.

Hong J, Woo HS, Kim H, Ahn HK, Sym SJ, Park J, Ahn JY, Cho EK, Shin DB, Lee JH - Cancer Sci. (2014)

Analyses of the impact of anemia on treatment outcomes in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy (n = 157). (a, b) Kaplan–Meier plots for event-free survival according to the grade of baseline anemia. (c) Kaplan–Meier plot for disease-free survival according to the grade of baseline anemia. (d, e) Kaplan–Meier graphs for event-free survival according to bone marrow status and baseline anemia.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317957&req=5

fig01: Analyses of the impact of anemia on treatment outcomes in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy (n = 157). (a, b) Kaplan–Meier plots for event-free survival according to the grade of baseline anemia. (c) Kaplan–Meier plot for disease-free survival according to the grade of baseline anemia. (d, e) Kaplan–Meier graphs for event-free survival according to bone marrow status and baseline anemia.
Mentions: The mean baseline Hb was 11.9 ± SD 1.8 g/dL in male patients and 10.9 ± SD 1.6 g/dL in female patients (P = 0.001). One hundred and twenty-one patients (77.1%) had G ≥ 1 and 34 patients (21.7%) had G ≥ 2 baseline anemia. Patients with a CIA of G ≥ 2 anemia showed inferior EFS compared to those with no (G0) or G1 anemia (Fig. 1a,b). Among 10 patients who had TRM, 7 had G ≥ 2 baseline anemia (P = 0.001). However, such a significant difference of survival between patients with G ≥ 2 anemia and those with G0 or 1 anemia was well maintained in analysis of DFS instead of EFS (P < 0.001; Fig. 1c).

Bottom Line: This finding was observed irrespective of the status of pre-treatment bone marrow involvement.In multivariate analysis, hemoglobin <10 g/dL was found to be an international prognostic index-independent prognostic factor.Risk of relapse was significantly higher for patients who were still anemic at 6 months after R-CHOP, compared to those who achieved complete recovery from chemotherapy-induced anemia within 6 months.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University School of Medicine, Incheon, Korea.

Show MeSH
Related in: MedlinePlus